Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Core Laboratories (CLB) EBIT Margin (2022 - 2026)

Core Laboratories filings provide 5 years of EBIT Margin readings, the most recent being 1.55% for Q1 2026.

  • On a quarterly basis, EBIT Margin fell 202.0% to 1.55% in Q1 2026 year-over-year; TTM through Mar 2026 was 1.35%, a 915.0% decrease, with the full-year FY2025 number at 1.83%, down 935.0% from a year prior.
  • EBIT Margin hit 1.55% in Q1 2026 for Core Laboratories, up from 22.42% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 15.56% in Q3 2025 to a low of 24.9% in Q4 2023.
  • Median EBIT Margin over the past 5 years was 11.3% (2024), compared with a mean of 5.92%.
  • Biggest five-year swings in EBIT Margin: tumbled -3714bps in 2023 and later surged 3586bps in 2024.
  • Core Laboratories' EBIT Margin stood at 12.24% in 2022, then tumbled by -303bps to 24.9% in 2023, then soared by 144bps to 10.97% in 2024, then tumbled by -304bps to 22.42% in 2025, then surged by 107bps to 1.55% in 2026.
  • The last three reported values for EBIT Margin were 1.55% (Q1 2026), 22.42% (Q4 2025), and 15.56% (Q3 2025) per Business Quant data.